StockWireNews

Complete Tuesday Update On Nasdaq Past Champ (BTCY)

January 25th

Greetings Readers,

You're not blind, the markets took a beating a good portion of yesterday.

That considered, here's 3 big reasons why BTCY should remain high on your watch list today.

First off, the company released this huge news yesterday: Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device

Quoted in the article was Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO: "We are extremely proud of this accomplishment and its potential to reshape the future of cardiac prevention and monitoring with this novel platform. With Biotres receiving 510(k) clearance, we now have another option for providing a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs. Coupled with the recent successful non-dilutive financing, we believe we are well capitalized to execute the expansion of our commercialization efforts."

Secondly, on top of that news was something that popped up mid-day. Check it out: Cedar Mountain Advisors, LLC Buys ARK Innovation ETF, Berkshire Hathaway Inc, Ford Motor Co, ...

In that article you'll find that a specific in-vest-ment company recently added to their current BTCY position.

Finally, BTCY closed the session in an interesting position from a technical standpoint.

With it falling below $3.00 potential support only to see it rise back above before the closing bell could be a significant sign of things to come.

What does that tell us exactly? It tells us that $3.00 could be a strong point of potential support in the days ahead.

And with this profile already displaying so many oversold leaning technicals, it may be seen as undervalued at current levels and ready for a potential near term reversal.

Take a moment now to read the two articles above, my initial report below, and then get this two-time past champ on your radar this moment.

-----

We've got to hurry so let's break down last week's breakout star, DATS.

DATS moved from an open of $2.46 to a high of $3.82 Tuesday for a crazy sized $1.00+ breakout.

That incredible intraday surge resulted in a run of approximately 55%.

But here's the thing, DATS wasn't done by a long shot.

On Thursday, it kept cooking as it blazed its way to a high of $4.14.

From $2.46 to $4.14, DATS turned into a stunner that ran approximately 68%.

Not bad for just a couple of days...

That said, it's a new week with new opportunities.

On multiple occasions, I've brought this profile to your attention and it has made $1.00+ moves after my alerts.

Now it could be lined up once again for another possible breakout due to 5 potential breakout catalysts.

So, for the morning of January 24th, there is only one profile to have on your radar:

*Biotricity, Inc. (BTCY)*

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets.

And right now BTCY has 5 potential catalysts that could spark it to a potential vertical surge near term.

Here's what you need to know:

No. 1 - Distribution On Amazon Could Be True Game-Changer

No. 2 - Bioheart Heart Monitor Product Now Available

No. 3 - Strong Balance Sheet And Revenue Growth Announcement

No. 4 - Key Technicals Could Signal Possible Near Term Healthy Reversal

No. 5 - Major Price Targets From 4 Different Analysts/Firms

But more on them in a second...

Its Foundational Product, Bioflux, is Targeting a Growing and Underserved Market

The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market.

Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor.

For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were.

And right now, BTCY has 5 potential catalysts that could spark a possible breakout. Here's what you need to know...

No. 1 Potential BTCY Breakout Catalyst - Distribution On Amazon Could Be True Game-Changer

Biotricity Expands Distribution of New Bioheart Device on Amazon

New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone

Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution

REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon(dot)com.

Last month the company launched commercial sales of its Bioheart device. To improve availability and expand outreach, Biotricity has now listed it for purchase on Amazon(dot)com at: Bioheart on Amazon for $199 with a special introductory price of $149 for a limited time. You can view the Bioheart heart monitor in use here.

"We are aiming to transform the cardiac health marketplace and believe the Bioheart system will play an important role in that endeavor," said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, "The Bioheart device is an important component of our full spectrum, ‘virtual cardiac clinic' of mobile cardiac care and lifestyle solutions. It will be fully integrated with a growing number of cardiology practices through our cloud-based ‘Biosphere' ecosystem that we plan to fully roll out in 2022, allowing physicians to get a more holistic view of a patient's health."

"The ability to offer Bioheart on Amazon expands the availability for the public to easily access the benefits of this exciting technology," Dr. Waqaas added.

The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company's total addressable market by $1.24B. Heart conditions are intermittent, requiring long-term data collection for effective insights and lifestyle management. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots and long-term data collection.

Introducing a groundbreaking new capability, users can collect data for hours, days, weeks, months, and even years! They can create snapshots of rhythm data by reviewing past data and marking it for personal records. These are first-of-its-kind features that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.

Read the full article here.

-----

No. 2 Potential BTCY Breakout Catalyst - Bioheart Heart Monitor Product Now Available

Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor

Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone

REDWOOD CITY, Calif., November 10, 2021--(BUSINESS WIRE)--Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www(dot)bioheart(dot)com.

The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. "Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey," said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.

Heart conditions are intermittent, requiring long term data collection for effective insights. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots. Introducing a groundbreaking new capability, users can create snapshots of rhythm data by reviewing past data and marking it for personal records. This is a first-of-its-kind feature that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.

Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm monitoring, to help individuals understand and improve their heart health. It provides 24/7 electrical heart rhythm monitoring and recording with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.

"Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimization and preventative cardiac wellness," said Dr. Al-Siddiq. "Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease."

[...]

"Bioheart has the potential to make an immediate, life-changing impact for those who use it," added Dr. Al-Siddiq. "As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season."

[...]

Read the full article here.

-----

No. 3 Potential BTCY Breakout Catalyst - Strong Balance Sheet And Revenue Growth Announcement

Biotricity Releases Fiscal 2022 Second Quarter Fin-an-cial Results

• Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth
• Strongest balance sheet since inception

REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced fin-an-cial results for its 2022 fiscal year's second quarter ended September 30, 2021.

[...]

"This was a historic quarter with our recent listing on the Nasdaq, in which we strengthened our balance sheet, and introduced our plans for Biokit and its commercial launch in the first quarter of calendar 2022," stated Dr. Waqaas Al-Siddiq, CEO and founder of Biotricity. "We have disclosed several other state-of-the-art remote cardiac monitoring devices and software apps in our development pipeline - all of which are planned for commercialization in 2022, pending FDA clearance where required."

[...]

Read the full article here.

-----

No. 4 Potential BTCY Breakout Catalyst - Key Technicals Could Signal Possible Near Term Healthy Reversal

As of close on Friday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term for BTCY.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of close Friday) that could signal BTCY to be leaning oversold and on the verge of a potential reversal.

• 9-Day Relative Strength Index: 37.72%
• 14-Day Relative Strength Index: 38.66%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

• 20-Day Raw Stochastic: 13.39%
• 20-Day Williams %R: 86.61%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

No. 5 Potential BTCY Breakout Catalyst - Major Price Targets From 4 Different Analysts/Firms

Since July 1st 2021, four different analysts have provided price targets of either $6.00 or $7.00 according to MarketBeat's website. Check them out:

H.C. Wainwright analyst, Kevin Dede, commented:

"We are initiating coverage of Biotricity with a Buy rating and setting a potentially conservative $6 price target not only on account of the horizontal expansion marketing its solution in cardiac care to 25,000 U.S. physicians, but also on the profound trajectory toward the full ecosystem of care monitoring solutions for cardiac-related and/or influenced chronic conditions such as diabetes, hypertension, kidney disease, among others.

And while Biotricity has growth avenues to incorporate artificial intelligence-driven automation into its remote monitoring of many facets of holistic cardiac care—the vertical expansion alluded to—we see Biotricity, on its cardiac solution, Bioflux, alone presenting an enticing in-vest-ment as Bioflux supports better outcomes while providing doctors avenues to offer greater services.

With the support of a fully FDA approved device and multiple insurance codes, Bioflux produces electrocardiogram (ECG or EKG) results while patients are living their normal lives. The readings, stored in the cloud, present physiological insight for physicians in determining the next course of action in long-term care, and in the meantime, doctors may choose an alternative course and demand another office visit, an additional income event beyond the only-a-phone-visit 'telehealth' financial paradigm. For this reason, in concert with broad insurance coverage—sensible, we think, in light of physically fragile patients needing full-time monitoring in recognizing a negative trigger event—we expect doctors to continue to buy and use Biotricity's Bioflux.

For perspective on scale, at $500 each, and roughly 2,000 patients per each of the 25,000 base U.S. cardiac physicians, that when added to additional devices and services required to address associated cardiac-related afflictions, points to a $50B addressable market, and greater detail on this assessment is provided later in this report.

From our perspective, longer-term targets tied to kidney disease and other associated cardiac issues, fail our need for tangible solutions from which to base projections and are not powering our current forecasts; however and more importantly, the development of the monitoring ecosystem clearly supports the large addressable opportunity point. Nearer-term growth comes on the addition of new sales professionals, filling out an effort Biotricity has not grandly supported to date, and where we expect their addition to drive the steep immediate sales ramp forecast here."

-----

BTCY Recap: 5 Potential Breakout Catalysts For This Nasdaq MedTech Profile

No. 1 - Distribution On Amazon Could Be True Game-Changer

No. 2 - Bioheart Heart Monitor Product Now Available

No. 3 - Strong Balance Sheet And Revenue Growth Announcement

No. 4 - Key Technicals Could Signal Possible Near Term Healthy Reversal

No. 5 - Major Price Targets From 4 Different Analysts/Firms

-----

Coverage is officially reinitiated on BTCY. When you have time later, do this:

Get BTCY on your radar now.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)